SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is currently seeing a surge in community discussion, driven by robust utility developments like the upcoming Toshi Mobile launch and new DeFi tools. Increased trading volume and a dedicated holder base are reinforcing its "Face of Base" narrative, with many seeing current price levels as a significant accumulation opportunity while anticipating potential major exchange listings.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Protagonist Therapeutics is trending amid intense market speculation of a potential acquisition by Johnson & Johnson, driven by its robust clinical pipeline. The community is actively discussing recent strong Phase 3 data for rusfertide in Polycythemia Vera and impressive Phase 2b results for icotrokinra in ulcerative colitis, which are garnering significant analyst upgrades and reinforcing bullish sentiment. These developments position PTGX as a compelling biotech M&A target with promising assets in immunology and hematology.

World Gold Trust - SPDR Gold MiniShares Trust

GLDM is currently trending due to a surge in safe-haven demand, driven by expectations of Federal Reserve rate adjustments, global economic uncertainties, and a weakening dollar. The investment community is actively discussing gold's critical role as a robust hedge against inflation and market volatility, with many viewing GLDM as a preferred, liquid vehicle for long-term portfolio stability.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

Roundhill Ether Covered Call Strategy ETF ($YETH) is a trending topic, primarily driven by its recent shift to weekly distributions, which has garnered significant attention from income-focused investors. While community discussions reveal mixed sentiment regarding its NAV performance relative to direct Ethereum exposure, bullish long-term price predictions for Ethereum are contributing to investor interest in the ETF's potential for substantial dividends.

Ethereum Classic

Ethereum Classic ($ETC) is trending amidst intense community debate, with many users expressing frustration over its lagging performance compared to other major cryptocurrencies. Despite widespread sentiment of being "stuck" at current levels and experiencing "fake pumps," a vocal segment of the community maintains long-term bullish conviction, actively accumulating and anticipating a significant breakout. Discussions frequently revolve around its historical cycles, perceived market manipulation, and the expectation for ETC to eventually reflect broader crypto market rallies.

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. It operates through the following segments: Healthcare and Non-Healthcare. The Healthcare segment develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions and therapeutics. The Non-Healthcare segment designs, develops, manufactures, markets and sells a broad portfolio of premium, high-performance audio products and services. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo Corp

Masimo is currently trending due to a federal jury's ruling ordering Apple to pay for patent infringement related to blood-oxygen monitoring, alongside the reinstatement of an import ban on certain Apple Watch models. The community is actively discussing potential outcomes, including licensing deals or an acquisition, while also noting Masimo's recent strong earnings and strategic divestiture of its consumer audio business to sharpen its focus on healthcare innovation. Many investors are observing oversold technical indicators, anticipating a potential rebound as these developments unfold.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is trending after highly positive TETON-2 study results showed Tyvaso's efficacy in Idiopathic Pulmonary Fibrosis (IPF), addressing a significant unmet medical need. This clinical success is driving community excitement about the stock's robust pipeline, market expansion potential in IPF, and broader leadership in pulmonary hypertension, positioning it as a powerhouse within the biotech sector.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Quoin Pharmaceuticals (QNRX) is a trending topic following its announcement of successful rapamycin target loadings for proprietary delivery technologies and a substantial private placement, extending its operational runway. The community is actively debating its extremely low float and recent institutional accumulation, with many speculating on a potential short squeeze given the advancements in its rare disease pipeline, while others eye its long-term potential for Netherton Syndrome treatment.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending as investors digest overwhelmingly positive Phase 3 data for relacorilant in platinum-resistant ovarian cancer, touting its potential as a new standard of care and sparking bullish long-term outlooks. This comes amid an eagerly awaited regulatory decision for relacorilant in Cushing's syndrome and notable survival data for its ALS candidate, fueling community speculation about a significant short squeeze against substantial short interest. Despite this excitement, some observers remain cautious, highlighting past earnings performance and recent stock volatility.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is trending amidst intense community debate, fueled by widespread accusations of a significant "rugpull" and calls of it being a "scam" project. Many investors are expressing extreme frustration, pointing fingers at its founder and suggesting a shift of capital towards other cryptocurrencies or booming AI stocks. This pervasive negative sentiment is amplified by fears of further declines, with some anticipating a broader "Christmas dump" across the altcoin market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

With all the buzz around $MRX, we dug up something interesting. 
On slide two: the event that raised serious questions about $MRX’s performance. 
 
We’re watching closely — and you should too. Stay tuned. 
 
https://11th.com/cases/marex-investor-suit

MRX investors filed a claim against Marex Group for making false and misleading statements in connection with its IPO, including misrepresenting financial s...

11th.com

Marex ($MRX) Omitted Forecasts and Misled Investors at IPO Case

StockTwits Web

Marex Group Plc

, we dug up something interesting. 
On slide two: the event that raised serious questions about 

’s performance. 
 
We’re watching closely — and you should too. Stay tuned. 
 
